Evidence map›Paper›PMID 31737793›Full record

ArticleBiochemistry and biophysics reports2019

Schwann cell-specific Dp116 is expressed in glioblastoma cells, revealing two novel

Abdul Qawee Mahyoob Rani, Kazuhiro Maeta, Tatsuya Kawaguchi, Hiroyuki Awano, Masashi Nagai, Hisahide Nishio, Masafumi Matsuo

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Lymphatic dysfunction is linked to disease pathogenesis in Duchenne muscular dystrophy animal models.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Intronic Alternative Polyadenylation in the Middle of theInternational journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Abdul Qawee Mahyoob RaniResearch Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe, 651-2180, Japan.
Kazuhiro MaetaResearch Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe, 651-2180, Japan.
Tatsuya KawaguchiTranslational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Edogawa, Tokyo, 134-8634, Japan.
Hiroyuki AwanoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Chuo, Kobe, 650-0017, Japan.
Masashi NagaiDepartment of Pediatrics, Kobe University Graduate School of Medicine, Chuo, Kobe, 650-0017, Japan.
Hisahide NishioResearch Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe, 651-2180, Japan.
Masafumi MatsuoResearch Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe, 651-2180, Japan.
Kobe Gakuin University · JPKobe University · JPDaiichi-Sankyo (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe

methodsFull-length Dp116 cDNA was PCR amplified from U-251 glioblastoma cells. Dp116 protein was analyzed by Western blotting.

resultsFull-length Dp116 cDNA, extending from exon S1 to exon 79, was PCR amplified to avoid confusion with other DMD isoforms. The full-length Dp116 transcript was amplified as nearly 3 kb in size. Western blotting of U-251 cell lysates revealed a signal at a position corresponding to vector-expressed Dp116 protein, indicating that Dp116 is expressed in glioblastoma cells. Sequencing of the amplified product revealed five splice variants, all skipping exon 78. The most abundant transcript lacked only exon 78 (Dp116b), whereas the second most abundant transcript lacked both exons 71 and 78 (Dp116ab). A third transcript lacking exons 71-74 and 78 was also identified (Dp116bc). Two novel splicing patterns were also observed, one with a deletion of exons 68 and 69 (Dp116bΔ68-69) and the other with a 100 bp deletion in the 5' terminal end of exon 75 (75s), which was produced by the activation of a cryptic splice acceptor site (Dp116b75s). However, the splicing patterns in glioblastoma cells of

conclusionsDp116 is expressed in glioblastoma cells as five splicing variants, with Dp116b being the most abundant. Two novel splicing patterns of

Indexed as

DMD geneDp116DystrophinGlioblastomaSplice variantsSplicing

Identifiers

PMID31737793
PMCPMC6849142
OpenAlexW2986749024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.